Cost Of Revenue - Genovis AB (STO:GENO) - Alpha Spread
G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 22.75 SEK 0.22% Market Closed
Market Cap: 1.5B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genovis AB
Cost of Revenue Peer Comparison

Comparables:
ALIF B
BICO
BIOT
MCAP
M
MAGLE

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Cost of Revenue
-kr45.2m
CAGR 3-Years
-43%
CAGR 5-Years
-64%
CAGR 10-Years
-12%
AddLife AB
STO:ALIF B
Cost of Revenue
-kr6B
CAGR 3-Years
-21%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Cost of Revenue
-kr1.1B
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Cost of Revenue
-kr774m
CAGR 3-Years
-20%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
MedCap AB (publ)
STO:MCAP
Cost of Revenue
-kr920.6m
CAGR 3-Years
-33%
CAGR 5-Years
-23%
CAGR 10-Years
-4%
M
Magle Chemoswed Holding AB
STO:MAGLE
Cost of Revenue
-kr16.5m
CAGR 3-Years
18%
CAGR 5-Years
-6%
CAGR 10-Years
N/A

See Also

What is Genovis AB's Cost of Revenue?
Cost of Revenue
-45.2m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Cost of Revenue amounts to -45.2m SEK.

What is Genovis AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-12%

Over the last year, the Cost of Revenue growth was -3%. The average annual Cost of Revenue growth rates for Genovis AB have been -43% over the past three years , -64% over the past five years , and -12% over the past ten years .

Back to Top